



Long-term outcomes in five patients with autoimmune pulmonary alveolar proteinosis treated with molgramostim inhalation solution

Copyright ©The authors 2025

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 3 June 2024
Accepted: 20 July 2024

To the Editor:

Autoimmune pulmonary alveolar proteinosis (aPAP), which accounts for >90% of all cases of PAP, is a rare lung disease mediated by granulocyte–macrophage colony-stimulating factor (GM-CSF) autoantibodies that block GM-CSF signalling, leading to reduced surfactant clearance causing abnormal accumulation of alveolar surfactant and impaired gas exchange [1–3]. The current standard of care for aPAP is whole-lung lavage (WLL), which is invasive, resource intensive, carries procedural risk, does not address the underlying cause of disease and often must be repeated regularly [4]. Hence, there is a therapeutic need to address the underlying pathophysiology of the disease. Studies have explored inhaled GM-CSF augmentation as a primary treatment for aPAP [5–12]. In this real-world case series, we present the beneficial long-term effects of molgramostim inhalation solution, an investigational, recombinant GM-CSF, in five aPAP patients with therapeutic disease challenges.

All five patients had classic computed tomography (CT) scan patterns, bronchoalveolar lavage findings and characteristic PAP symptoms coupled with a positive GM-CSF autoantibody test, leading to a diagnosis of aPAP. All patients received inhaled molgramostim administered using a vibrating mesh nebuliser (eFlow, PARI Pharma) as part of a compassionate-use programme established by Savara Inc. and in compliance with regulations in the patients' countries. Table 1 shows high-resolution CT scans and clinical measures for each patient before treatment with molgramostim and after remaining on therapy for varying periods. There were no reported serious adverse events in these five patients while receiving molgramostim and the treatment has been well tolerated.

Patient 1 was a male diagnosed with aPAP at 27 years of age and presented with a 2-month history of progressive dyspnoea requiring $8\text{ L}\cdot\text{min}^{-1}$ oxygen at rest. In February 2019, a WLL was performed once on the left side and 3 months later, on the right side. Given that this was a young patient with severely impaired lung function, severe limitation of daily activities and the need for supplemental oxygen, the patient began therapy with molgramostim in June 2019. After starting therapy, steady clinical improvement was observed with a 54% increase in predicted diffusing capacity of the lung for carbon monoxide (D_{LCO}), and a simultaneous decrease in the need for supplemental oxygen and increases in tolerance to physical exertion. Currently, the patient is leading a self-described “normal everyday life” and can work as he did before the onset of the disease.

Patient 2 was a female who presented in December 2018 at age 28 with 3 days of influenza-like symptoms including musculoskeletal pain, fever, vomiting, diarrhoea and progressive breathlessness. She was hospitalised and immediately transferred to the intensive care unit due to respiratory failure. In March 2020, the patient presented to a specialised interstitial lung disease clinic with cough and progressive dyspnoea. Molgramostim was started immediately after diagnosis of aPAP in March 2020, and the patient showed significant improvement in D_{LCO} and forced vital capacity.

In patient 3, diagnosis of aPAP was made at 31 years of age. He worked as a technical engineer and was subjected to dust exposure. The patient had been stable for 4 years without any treatment. However, in July



Shareable abstract (@ERSpublications)

This real-world case series presents the beneficial long-term effects of molgramostim inhalation solution, an investigational, recombinant GM-CSF, in five patients with severe aPAP who received molgramostim on a compassionate-use basis <https://bit.ly/3ypPhJl>

Cite this article as: Montaña C, Bendstrup E, Rønnov-Jessen I, *et al.* Long-term outcomes in five patients with autoimmune pulmonary alveolar proteinosis treated with molgramostim inhalation solution. *ERJ Open Res* 2025; 11: 00567-2024 [DOI: 10.1183/23120541.00567-2024].













TABLE 1 Presentation and treatment of five adults with autoimmune pulmonary alveolar proteinosis

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age at presentation (years)	27	29	31	21	46
Age at last follow-up (years)	31	33	40	32	52
Sex	Male	Female	Male	Female	Male
Initial presentation	Progressive dyspnoea, need 8 L·min ⁻¹ O ₂ at rest	Influenza-like symptoms including muscle-joint pain, fever, vomiting, diarrhoea, and progressive breathlessness	Dyspnoea, cough, need 4 L·min ⁻¹ O ₂ at rest	Cough and progressive exertional dyspnoea and chest tightness	Cough, chest pain, dyspnoea on exercise
CT scan with crazy-paving pattern	Yes	Yes	Yes	Yes	Yes
BAL with milky appearance, granular eosinophilic material	Yes	Yes	Not done	Yes	Yes
Lung biopsy with alveolar spaces filled with homogeneously eosinophilic, PAS-positive material	Yes	Not done	Yes	Yes	Not done
Anti-GM-CSF antibody	Positive	Positive	Positive	Positive	Positive
WLL number before/after	2 (within 1 year)/0	Not done	4 (within 1 year)/0	8 (within 4 years)/0	3 (within 1 year)/0
FVC (% pred) initial/last	64/74	83/122	52/71	73/88	54/75
<i>D</i> _{Lco} (% pred) initial/last	10% increase	39% increase	19% increase	15% increase	21% increase
<i>P</i> _{ao₂} (mmHg) or <i>S</i> _{pO₂} (%) initial/last	37/91	36/60	39/87	62/90	12/44
Reduction in <i>D</i> _{A-aO₂} from initial visit to last follow-up (mmHg)	54% increase	24% increase	48% increase	28% increase	32% increase
Disease severity score Initial/last	56 mmHg/74 mmHg	90%/99%	95%/NA [#]	66.7 mmHg/85.4 mmHg	77 mmHg (with 3 L·min ⁻¹ O ₂)/80 mmHg (room air)
Time on molgramostim (years)	-47.4	NA	NA	-20.6	-52.9
Molgramostim dose	4/1	4/2	4/NA [#]	3/1	5/2
Molgramostim dose	4.5	3.5	5.5	4 and previous 1 year in IMPALA trial	1.5 and previous 1 year in IMPALA trial
Molgramostim dose	300 µg·day ⁻¹	March 2020–Feb 2021, 250 µg·day ⁻¹ Feb 2021, 250 µg every other day March–April 2021, no treatment April 2021–May 2022, 250 µg·day ⁻¹ May 2022, 250 µg every other day until present	300 µg·day ⁻¹	300 µg·day ⁻¹ every other week	Dec 2017–Dec 2018, 300 µg·day ⁻¹ every other week Dec 2018–Jan 2023, no treatment Jan 2023–present 300 µg·day ⁻¹

Continued

TABLE 1 Continued

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Clinical outcome	Overall improvement Decrease in oxygen demand Improved PFTs and radiological findings	Rapid clinical improvement Improved PFTs and radiological findings	Improved No longer needed O ₂ supplementation Improved PFTs and radiological findings	Improved, without further need for O ₂ supplementation Improved PFTs and radiological findings	Improved, without need for O ₂ at rest Improved PFTs and radiological findings
HRCT before treatment with molgramostim inhalation solution	Jan 2019 	March 2020 	Jan 2018 	Aug 2018 	Dec 2022 [†] 
HRCT after treatment with molgramostim inhalation solution	June 2020, after 1 year on molgramostim 	Jan 2021, after 10 months on molgramostim 	June 2023, after 3.5 years on molgramostim 	Aug 2022, after 4 years on molgramostim 	Feb 2024, after 14 months on molgramostim 

CT: computed tomography; BAL: bronchoalveolar lavage; PAS: periodic acid–Schiff staining; GM-CSF: granulocyte–macrophage colony-stimulating factor; WLL: whole-lung lavage; FVC: forced vital capacity; D_{LCO} : diffusing capacity of the lung for carbon monoxide; P_{aO_2} : arterial oxygen tension; S_{pO_2} : oxygen saturation measured by pulse oximetry; D_{A-aO_2} : alveolar–arterial oxygen concentration difference; NA: not available; PFT: pulmonary function test; HRCT: high-resolution computed tomography. [#]: there was no S_{pO_2} or disease severity score captured on last follow-up for patient 3; [†]: HRCT after three WLLs that year and just after the third.

2017, the patient presented with cough and required $4 \text{ L} \cdot \text{min}^{-1}$ oxygen at rest. In 2018, the patient underwent four WLLs within a period of 4 months (two times on the right and two times on the left). The patient began molgramostim in December 2018. The patient showed considerable improvement within the first year of therapy with reduced shortness of breath and cough, and he no longer required oxygen supplementation at rest. No further WLL was required after the initiation of molgramostim therapy.

Patient 4 was a 21-year-old female who presented in 2012 with a 6-month history of cough, progressive exertional dyspnoea and chest tightness. Because of worsening hypoxaemia, the patient underwent WLL, ultimately having eight WLLs over the course of 4 years. From September 2018 to September 2019, the patient was involved in a randomised controlled clinical trial evaluating the safety and efficacy of inhaled molgramostim in patients with aPAP (IMPALA trial) [12], and since January 2020, the patient has been on molgramostim without further need for WLL or oxygen supplementation. The patient reports that the most significant effects of being on molgramostim are reduction in tiredness and no longer requiring supplemental oxygen.

Patient 5, an athletic 46-year-old male, presented in 2017 with a 6-month history of cough, chest pain and shortness of breath on exertion; he could no longer run. From December 2017 to December 2018, he participated in the IMPALA trial [12], and after receiving molgramostim showed clinical, functional and radiological improvement. The patient was asymptomatic until 2021, when he reported progressive respiratory decline. He was admitted to the hospital three times for respiratory failure secondary to infections and disease progression. WLL was performed in both lungs three times in 2022 with partial improvement. The patient required oxygen supplementation at rest and was referred for an evaluation for lung transplantation. The patient restarted molgramostim in January 2023 with rapid and significant clinical, functional and radiological improvement. No WLL has been performed since then nor have there been further hospitalisations. Currently, the patient does not need supplemental oxygen and he has returned to work.

Patients with aPAP are frequently misdiagnosed with pneumonia based on radiological findings or asthma based on nonspecific symptoms until the failure to respond to “appropriate” therapy prompts reconsideration of the diagnosis; in such cases, an accurate diagnosis is delayed on average by 18 months [13]. Results from the US National PAP Registry indicate many patients with PAP undergo transbronchial biopsy, surgical lung biopsy or both even though neither is diagnostic for any PAP-causing disease, and both are associated with sampling error and significant procedure-related morbidity [13]. Despite our understanding of aPAP pathophysiology, the path to a definitive diagnosis can be challenging. However, the availability of a serum GM-CSF autoantibody test to diagnose aPAP has rendered lung biopsies unnecessary in most cases [14].

There are no data yet to support the long-term benefits of inhaled GM-CSF. In this case series, none of the five patients required WLL after >1 year on molgramostim, suggesting that molgramostim therapy may have prevented the need for WLL in these patients. Moreover, in one case, a patient received molgramostim as first-line therapy because of an inability to schedule a WLL and she ultimately avoided WLL completely. Furthermore, the improvements in disease severity, gas transfer measured by D_{LCO} and alveolar-arterial oxygen gradient when available, and activities of daily living were maintained over time. The main limitation of this case series is the retrospective nature of the data collected from real-world clinical practice.

An overarching theme in these patients’ stories is an apparent significant healthcare burden on aPAP patients in terms of initial misdiagnosis, procedures, therapy use, healthcare utilisation and costs. Patients with aPAP have significantly higher rates of healthcare utilisation and comorbidities, with 66% more outpatient visits, 38% more emergency department visits and hospital stays that are three times longer when compared with age- and gender-matched control patients [15].

The present data suggest that the use of molgramostim in a real-world clinical setting provides a pharmacological approach to addressing the underlying pathophysiology of aPAP resulting in improved lung function, decreased disease burden, restored patient functionality and reduction of clinical symptoms allowing for a resumption of activities of daily life.

Celia Montaña¹, Elisabeth Bendstrup², Ida Rønnov-Jessen², Sara Salgado³, Georg Sterniste⁴, Arshang Valipour⁴, Marcel Veltkamp^{5,6} and María Molina-Molina¹

¹Interstitial Lung Diseases Unit, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), CIBERES, Barcelona, Spain. ²Center for Rare Lung Diseases, Department of Respiratory

Diseases and Allergy, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. ³Pulmonology Department, Interstitial Lung Diseases Unit, Pulido Valente Hospital, Lisbon, Portugal. ⁴Department of Respiratory and Critical Care Medicine, Karl-Landsteiner-Institute for Lung Research, Vienna Health Care Group, Klinik Floridsdorf, Vienna, Austria. ⁵ILD Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands. ⁶Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands.

Corresponding author: Maria Molina-Molina (mariamolinamolina@hotmail.com)

Provenance: Submitted article, peer reviewed.

Acknowledgements: The authors thank Brian Robinson (Savara Inc.) for providing editorial support in preparing the manuscript.

Author contributions: Conception and design: E. Bendstrup, S. Salgado, A. Valipour, M. Veltkamp and M. Molina-Molina. Acquisition of data: all authors. Analysis and/or interpretation of data: all authors. Drafting the manuscript: C. Montaña and M. Molina-Molina. Revising the manuscript critically for important intellectual content: all authors. Approval of the version of the manuscript to be published: all authors.

Conflict of interest: C. Montaña reports receiving support for the present manuscript from Savara. E. Bendstrup reports receiving support for the present manuscript from Savara; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Boehringer Ingelheim, Hofmann la Roche, Daiichi-Sankyo and AstraZeneca, outside the submitted work; support for attending meetings and/or travel from Boehringer Ingelheim outside the submitted work; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Veracyte and Simbec, outside the submitted work. I. Rønnov-Jessen reports receiving support for the present manuscript from Savara. S. Salgado reports receiving support for the present manuscript from Savara. G. Sterniste reports receiving support for the present manuscript from Savara. A. Valipour reports receiving support for the present manuscript from Savara. M. Veltkamp reports receiving support for the present manuscript from Savara. M. Molina-Molina reports receiving support for the present manuscript from Savara; grants received from Boehringer Ingelheim outside the submitted work; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events for Boehringer Ingelheim, Roche, Ferrer and Janssen, outside the submitted work; and support for attending meetings and/or travel from Boehringer Ingelheim, outside the submitted work.

Support statement: This study was supported by Savara Inc. enabling molgramostim use through a compassionate-use programme. Funding information for this article has been deposited with the Crossref Funder Registry.

References

- 1 Inoue Y, Trapnell BC, Tazawa R, *et al.* Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. *Am J Respir Crit Care Med* 2008; 177: 752–762.
- 2 Campo I, Mariani F, Rodi G, *et al.* Assessment and management of pulmonary alveolar proteinosis in a reference center. *Orphanet J Rare Dis* 2013; 8: 40.
- 3 Kitamura T, Tanaka N, Watanabe J, *et al.* Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. *J Exp Med* 1999; 190: 875–880.
- 4 Awab A, Khan MS, Youness HA. Whole lung lavage-technical details, challenges and management of complications. *J Thorac Dis* 2017; 9: 1697–1706.
- 5 Seymour JF, Dunn AR, Vincent JM, *et al.* Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. *N Engl J Med* 1996; 335: 1924–1925.
- 6 Ohashi K, Sato A, Takada T, *et al.* Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis. *Respir Med* 2012; 106: 284–293.
- 7 Seymour JF, Presneill JJ, Schoch OD, *et al.* Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. *Am J Respir Crit Care Med* 2001; 163: 524–531.
- 8 Venkateshiah SB, Yan TD, Bonfield TL, *et al.* An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. *Chest* 2006; 130: 227–237.
- 9 Tazawa R, Hamano E, Arai T, *et al.* Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. *Am J Respir Crit Care Med* 2005; 171: 1142–1149.

- 10 Tazawa R, Ueda T, Abe M, *et al.* Inhaled GM-CSF for pulmonary alveolar proteinosis. *N Engl J Med* 2019; 381: 923–932.
- 11 Tian X, Yang Y, Chen L, *et al.* Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis—a six-month phase II randomized study with 24 months of follow-up. *Orphanet J Rare Dis* 2020; 15: 174.
- 12 Trapnell BC, Inoue Y, Bonella F, *et al.* Inhaled molgramostim therapy in autoimmune pulmonary alveolar proteinosis. *N Engl J Med* 2020; 383: 1635–1644.
- 13 McCarthy C, Carey B, Trapnell BC. Blood testing for differential diagnosis of pulmonary alveolar proteinosis syndrome. *Chest* 2019; 155: 450–452.
- 14 McCarthy C, Carey BC, Trapnell BC. Autoimmune pulmonary alveolar proteinosis. *Am J Respir Crit Care Med* 2022; 205: 1016–1035.
- 15 McCarthy C, Avetisyan R, Carey BC, *et al.* Prevalence and healthcare burden of pulmonary alveolar proteinosis. *Orphanet J Rare Dis* 2018; 13: 129.